Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07626-5Source: DataRank Database

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer is a research paper published in Breast Cancer Research and Treatment (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.64)OA: hybridTopics (61)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Margarite D. Matossian ORCID,Poornima Saha ORCID,Murtuza Rampurwala ORCID,Sailaja Kamaraju ORCID,Olwen Hahn

Live enrichment

PubMed:39928262 OpenAlex:https://openalex.org/W4407290924

National Cancer Institute

Grant: K08CA283261

National Institutes of Health

Grant: T32GM007019

National Institute on Aging

Grant: T32AG000243

National Institutes of Health

Grant: 3T32AG000243-15S1

Specialized Training: Demography & Economics of Aging

National Institutes of Health

Grant: 5K08CA283261-02

Integrating Clinical, Pathologic, and Immune Features to Predict Breast Cancer Recurrence and Chemotherapy Benefit

National Institutes of Health

Grant: 3P30CA014599-36S1

Cancer Center Support Grant

National Institutes of Health

Grant: 5T32GM007019-13

CLINICAL THERAPEUTICS

National Institutes of Health

Grant: 5T32CA009566-19

Basic Medical Research Training in Medical Oncology

NCI NIH HHS

Grant: P30 CA014599

NCI NIH HHS

Grant: T32 CA009566

FWCI

2.64

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s10549-025-07626-5.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-025-07626-5.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-025-07626-5/fulltext.html

journalhttps://doi.org/10.1007/s10549-025-07626-5

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39928262

Fields of Study

Estrogen and related hormone effectsBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research03 medical and health sciences0302 clinical medicineHumansFemaleTriple Negative Breast NeoplasmsPaclitaxelMiddle AgedAlbuminsMifepristoneAntineoplastic Combined Chemotherapy ProtocolsAdultAgedTreatment OutcomeNeoplasm StagingReceptors, Glucocorticoid

MeSH Terms

AdultAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMiddle AgedNeoplasm StagingReceptors, GlucocorticoidMifepristoneTreatment OutcomePaclitaxelTriple Negative Breast Neoplasms

Keywords

MedicineClinical endpointMifepristoneTriple-negative breast cancerNeutropeniaInternal medicineOncologyPaclitaxelBreast cancerInterim analysisRandomized controlled trialChemotherapyCancerBiologyAdultResearchTriple Negative Breast NeoplasmsMiddle AgedTreatment OutcomeReceptors, GlucocorticoidAlbuminsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedNeoplasm StagingClinical trialGlucocorticoid receptorHER2- breast cancerNab-paclitaxel

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being